Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients
about
Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkersSimultaneous analyses of N-linked and O-linked glycans of ovarian cancer cells using solid-phase chemoenzymatic methodGlycomic analysis of sialic acid linkages in glycans derived from blood serum glycoproteins.Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling.The effects of abundant plasma protein depletion on global glycan profiling using nanoLC FT-ICR mass spectrometry.Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery.Comparing MALDI-MS, RP-LC-MALDI-MS and RP-LC-ESI-MS glycomic profiles of permethylated N-glycans derived from model glycoproteins and human blood serumThe N-glycome of human plasma.Resolving the problem of chromatographic overlap by 3D cross correlation (3DCC) processing of LC, MS and NMR data for characterization of complex glycan mixtures.One-Year Plasma N-linked Glycome Intra-individual and Inter-individual Variability in the Chicken Model of Spontaneous Ovarian Adenocarcinoma.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.A MALDI-MS-based quantitative targeted glycomics (MALDI-QTaG) for total N-glycan analysis.Structural Characterization of Carbohydrates by Fourier Transform Tandem Mass Spectrometry.Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers.Delineating diseases by IMS-MS profiling of serum N-linked glycans.Microfluidic Chip-LC/MS-based Glycomic Analysis Revealed Distinct N-glycan Profile of Rat Serum.Development of a hydrophilic interaction liquid chromatography coupled with matrix-assisted laser desorption/ionization-mass spectrometric imaging platform for N-glycan relative quantitation using stable-isotope labeled hydrazide reagents.Ion mobility-mass spectrometry analysis of serum N-linked glycans from esophageal adenocarcinoma phenotypesAutomated glycopeptide analysis--review of current state and future directionsDevelopment of a robust and high throughput method for profiling N-linked glycans derived from plasma glycoproteins by NanoLC-FTICR mass spectrometry.Glycomics and disease markers.High-sensitivity analytical approaches for the structural characterization of glycoproteins.Glycan analysis by modern instrumental methods.Application of nano-LC-based glycomics towards biomarker discovery.Recent advances in hydrophilic interaction liquid chromatography (HILIC) for structural glycomics.Nano-liquid chromatography in pharmaceutical and biomedical research.High resolution mass spectrometry based techniques at the crossroads of metabolic pathways.Stable-isotope labeled hydrophobic hydrazide reagents for the relative quantification of N-linked glycans by electrospray ionization mass spectrometry.Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression.Glycoproteomics-based identification of cancer biomarkers.Reversed-phase separation methods for glycan analysisLC-MS/MS of permethylated N-glycans derived from model and human blood serum glycoproteins.Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer.Systematic comparison of reverse phase and hydrophilic interaction liquid chromatography platforms for the analysis of N-linked glycans.Mass spectrometry for protein sialoglycosylation.A novel carbon material with nanopores prepared using a metal-organic framework as precursor for highly selective enrichment of N-linked glycans.
P2860
Q28079101-30E4C253-2777-4450-B5FC-A55CD51782A2Q28468580-D3285E31-7E5C-4788-9968-3821EAE06C6CQ33546544-CA12BE83-87C9-4549-96B5-BB4ED7C0F890Q33653461-5404A534-0130-4871-BFAF-1AA3F6076010Q33836040-C306CE0E-8A3D-449E-98E7-1CB2C433D25CQ34022368-9330AEC4-2A0E-4B99-847E-0A61E1C1FA89Q34074809-868A58A9-9DDD-4953-B5EE-799EB897AC9FQ34104742-7FFE1355-E1A3-4E0D-973A-75216B6EBABCQ34343373-E5C06539-87EF-4D34-9722-AC548C6FB328Q35161829-1F881DF6-86C9-49C9-8AD8-B42E85DD0DE8Q35174495-61ADC975-9A02-4C64-8F68-E6FB8CF1BDC9Q35660636-D1170557-4DF8-453F-AF34-3D9C7B0B3C78Q35786742-000B17E2-B098-449B-B432-87FBE62B8576Q35902976-D80B4437-7722-487B-B8BA-7F6EBA9112DFQ35913954-6662B2BB-7113-4F60-BF77-927D142A18FBQ36293747-79D9FF8F-CBA1-49E1-9F26-7230AD746AC6Q36379607-5D1A487F-0B69-4083-A2CB-2CDD3E710E6AQ36501921-338EDC5D-2770-4CFE-847F-8F1CE1E84168Q36860100-C85A788F-BCC3-451A-9BFA-B923C64DE038Q37084546-D663A8EE-3421-4E1C-A99C-CBCD77ECFC1AQ37457130-80684144-E70F-4112-A19F-3DF038B42BF3Q37712517-ACF7A3DE-19DA-4F5C-BA26-282D563F50AFQ37829419-7B4B5ADF-8371-456B-8C54-B683C8796225Q37961971-0E59F87E-AE05-447F-B725-8250C0A58764Q37969700-7162D43A-E9E0-48A6-BA89-17AFF2475A2DQ38098981-99211D9E-D7F3-467F-B6B7-A80305E620F7Q38167286-9F9E0D6B-2F3E-44B0-B51B-AD95BAED4A9EQ38604842-4E742256-E3C3-4E80-8840-CCE7754BC8C6Q38697958-C0E78A5A-7422-46FC-A932-34B4A143C2CFQ38738207-B933FF99-D7C2-4EB6-BD34-D33053D98EF2Q39020352-84EACB1E-0D8E-4047-8F47-64C67D4FC508Q39934984-AA85E524-CB89-4A7B-BE96-C6C9BEC2EFC3Q42279918-46B4BE21-4FE4-4531-BA5D-366B85B1BD7EQ43119550-26FBE46B-D393-4D45-9579-54B5803CDC47Q46243684-C027BEC4-45AD-47F5-B886-D4DB4A285C29Q51598241-16C60586-429B-4479-A89B-305F7736FAE2
P2860
Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@ast
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@en
type
label
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@ast
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@en
prefLabel
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@ast
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@en
P2093
P2860
P356
P1433
P1476
Development of a nanoLC LTQ or ...... helial ovarian cancer patients
@en
P2093
David C Muddiman
Michael S Bereman
Taufika Islam Williams
P2860
P304
P356
10.1021/AC802262W
P407
P577
2009-02-01T00:00:00Z